Chemotherapy-Induced Nausea and Vomiting: Rationale for Cost-Effective Management

Coates A. , Abraham S. , Kaye S.B. On the receiving end: patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol. 1983; 19: 203–208.

Bliss J.M. , Robertson B. , Selby P.J. The effect of nausea and vomiting upon quality of life measures. Br J Cancer. 1992; 66(Suppl 19): 14S–23S.

Martin M. Myths and realities of antiemetic treatment. Br J Cancer. 1992; 19(Suppl): S46–S50.

Gralla R. Adverse effects of treatment. In: DeVita V.T. , Hellman S. , Rosenberg S.A. , eds. Cancer: Principles and Practice of Oncology, 4th ed. Philadelphia, Pa: Lippincott. 1993: 2338–2348.

Cubedda L.X. , Hoffmann I.S. , Fuenmayer N.T. Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting. N Engl J Med. 1990; 322: 810–16.

Lindley C.M. , Bernard S. , Fields S.M. Incidence and duration of chemotherapy-induced nausea and vomiting in the outpatient oncology population. J Clin Oncol. 1989; 7: 1142–1149.

McEvoy G.K. , Litvak K. , Welsh O.H. AHFS drug information. Bethesda, Md: American Health-System Pharmacists, 1995.

Hainsworth J. , Harvey W. , Pendergrass K. A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy. J Clin Oncol. 1991; 9: 721–728.

Marty M. , Pouillart P. , Scholl S. Comparison of the 5-hydroxytryptamine-3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. N Engl J Med. 1990; 322: 816–821.

Italian Group for Antiemetic Research. Ondansetron plus dexamethasone vs metoclopramide plus dexamethasone plus diphenhydramine in prevention of cisplatin-induced emesis. Cancer Chemother Pharmacol. 1993; 50: 163–167.

De Mulder P.H. , Seynaeve C. , Vermorken J.B. Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. Ann Intern Med. 1990; 113: 834–840.

Kris M.G. Rationale for combination antiemetic therapy and strategies for the use of ondansetron in combinations. Semin Oncol. 1992; 19(Suppl 4): 61–66.

Roila F. , Tonato M. , Cognetti F. Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone. J Clin Oncol. 1991; 9: 675–678.

Noble A. , Bremer K. , Goedhals L. A double-blind, randomized, crossover comparison of granisetron and ondansetron in 5-day fractionated chemotherapy: assessment of efficacy, safety and patient preference. Eur J Cancer. 1994; 30A: 1083–1088.

Gebbia V. , Cannata G. , Testa A. Ondansetron versus granisetron in the prevention of chemotherapy-induced nausea and vomiting. Cancer. 1994; 74: 1945–1952.

Ruff P. , Paska W. , Goedhals L. Ondansetron compared with granisetron in the prophylaxis of cisplatin-induced acute emesis: a multicentre double-blind, randomized, parallel-group study. Oncology. 1994; 51: 113–118.

Jantunen I.T. , Muhonen T.T. , Kataja V.V. 5-HT3 receptor antagonists in the prophylaxis of acute vomiting induced by moderately emetogenic chemotherapy: a randomized study. Eur J Cancer. 1993; 29A:

Van Wijngaarden I. , Tulp M.T. , Soudijn W. The concept of selectivity in 5-HT receptor research. Eur J Pharmacol. 1990; 188:

Gandara D.R. , Harvey W.H. , Monaghan G. The delayed-emesis syndrome from cisplatin: phase III evaluation of ondan-setron versus placebo. Semin Oncol. 1992; 19(Suppl 10): 10; 67–71.

Kris M.G. , Tyson L.B. , Clark R.A. Oral granisetron for the control or delayed emesis after cisplatin. Cancer. 1992; 70(Suppl 4): 1012–1016.

Kris M.G. , Gralla R.J. , Tyson L.B. Controlling delayed vomiting: double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin. J Clin Oncol. 1989; 7: 108–114.

Grunberg S.M. , Stevenson L.L. , Russell C.A. Dose-ranging phase I study of the serotonin antagonist GR38032F for prevention of cisplatin-induced nausea and vomiting. J Clin Oncol. 1989; 7: 1137–1141.

Beck T.M. , Hesketh P.J. , Madajewicz S. Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting. J Clin Oncol. 1992; 10: 1969–1975.

Walton S.C. , Koenig T.J. Effectiveness and economy of low-dose ondansetron. Am J Health Syst Pharm. 1995; 52: 546–547.

Hesketh P.J. , Beck T. , Uhlenhopp M. Adjusting the dose of intravenous ondansetron plus dexamethasone to the emetogenic potential of the chemotherapy regimen. J Clin Oncol. 1995; 13: 2117–2122.

Navari R. , Gandara D. , Hesketh P. Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. J Clin Oncol. 1995; 13: 1242–1248.

Navari R.M. , Kaplan H.G. , Gralla R.J. Efficacy and safety of granisetron, a selective 5-hydroxytryptamine-3 receptor antagonist in the prevention of nausea and vomiting induced by high-dose cisplatin. J Clin Oncol. 1994; 12: 2204–2210.

Bleiberg H.H. , Spielmann M. , Falkson G. Antiemetic treatment with oral granisetron in patients receiving moderately emetogenic chemotherapy: a dose-ranging study. Clin Ther. 1995; 17: 38–50.

Heron J.F. , Goedhals L. , Jordaan J.P. Oral granisetron alone and in combination with dexamethasone: a double-blind randomized comparison against high-dose metoclopramide plus dexamethasone in prevention of cisplatin-induced emesis. Ann Oncol. 1994; 5: 579–584.

Field M.J. , Lohr K.N. , eds. Clinical practice guidelines: directions for a new agency. Institute of Medicine, Committee on Clinical Practice Guidelines. Washington, DC, National Academy Press, 1990.

Berard C.M. , Mahoney C.D. Cost-reducing treatment algorithms for antineoplastic drug-induced nausea and vomiting. Am J Health Syst Pharm. 1995; 52: 1879–1885.